A. Tusnádi

发表

IL28B and IL10R −1087 polymorphisms are protective for chronic genotype 1 HCV infection and predictors of response to interferon-based therapy in an East-Central European cohort

J. Féher, J. Gervain, M. Papp, 2014, BMC Research Notes.

[What is expected from the novel triple combination antiviral treatment of patients infected with hepatitis C virus genotype 1?].

A. Tusnádi, A. Szabó, 2013, Orvosi hetilap.

Cytokine (IL-10, IL-28B and LT-A) gene polymorphisms in chronic hepatitis C virus infection

J. Féher, J. Gervain, M. Papp, 2011 .

[IL28B CC genotype: a protective factor and predictor of the response to interferon treatment in chronic hepatitis C virus infection].

J. Féher, J. Gervain, M. Papp, 2013, Orvosi hetilap.

[Ulcerative colitis associated with pyoderma gangrenosum].

G. Krasznai, A. Tusnádi, K. Uhrin, 1994, Orvosi hetilap.

Real-World Virologic Response Rates and Prediction of Outcomes with Peginterferon Alfa-2a/Ribavirin in Hungarian HCV Genotype 1 Patients

J. Gervain, B. Hunyady, I. Tornai, 2014 .

Ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin in HCV genotype 1 infected patients who failed previous protease inhibitor therapy

J. Gervain, C. Sarrazin, B. Hunyady, 2018, Clinical and experimental hepatology.

Prevalence of gastrointestinal disease caused by Clostridium difficile in a university hospital in Hungary.

E. Urbán, E. Nagy, G. Terhes, 2002, The Journal of hospital infection.

Predictive value of FIB-4 and APRI versus METAVIR on sustained virologic response in genotype 1 hepatitis C patients

A. Horban, P. Ferenci, M. Curescu, 2013, Hepatology International.